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A meta-analysis using data from seven German population-based cohorts was performed
by the German Epidemiological consortium of Peripheral Arterial Disease (GEPArD) to
investigate whether one question about claudication is more efficient for PAD screening
than established questionnaires. Claudication was defined on the basis of the answer to one
question asking for pain in the leg during normal walking. This simple question was com-
pared with established questionnaires, including the Edinburgh questionnaire. The associa-
tions of claudication with continuous ABI values and decreased ABI were analyzed by linear
and logistic regression analysis, respectively. The results of the studies were pooled in a
random effect meta-analysis, which included data from 27,945 individuals (14,052 women,
age range 20–84 years).
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Results
Meta-analysis revealed a significant negative association between claudication and ABI,
which was stronger in men (β = -0.07; 95%CI -0.10, -0.04) than in women (β = -0.02; 95%CI
-0.02, -0.01). Likewise, the presence of claudication symptoms was related to an increased
odds of a decreased ABI in both men (Odds ratio = 5.40; 95%CI 4.20, 6.96) and women
(Odds ratio = 1.99; 95%CI 1.58, 2.51).
Conclusions
Asking only one question about claudication was able to identify many individuals with a
high likelihood of a reduced ABI with markedly higher sensitivity and only slightly reduced
specificity compared to more complex questionnaires. At least in men, this question should
be established as first screening step.
Introduction
Peripheral arterial disease
Peripheral arterial disease (PAD) is an underdiagnosed disease with high cardiovascular and
cerebrovascular morbidity and mortality[1, 2]. It affects over 200 million adults around the
world[3] and is associated with a relevant number of major adverse limb events (MALE)[4, 5].
Therefore current guidelines recommend to implement and support medical and public
awareness of PAD[1]. While prognostic improvement of interventional or surgical treatment
of stable PAD could not be demonstrated so far, exercise, smoking cessation, healthy diet,
weight loss in overweight people and pharmacological prophylaxis may prevent major adverse
cardiovascular events (MACE) and major adverse limb events (MALE), especially if PAD is
diagnosed at an earlier clinical stage. For example, aggressive lipid lowering therapy can reduce
major adverse cardiovascular and limb events in PAD patients[6], with a larger risk reduction
in comparison to atherosclerotic patients without PAD.
In a study with 18500 French general practitioners, intermittent claudication was well
known, but knowledge of recommendations for further diagnostic workup and treatment of
PAD was poor[7].
In order to diagnose most individuals with PAD, regular measurements of the ankle-bra-
chial index (ABI) in the whole population starting at an age of about 40 years seem to be useful.
Currently, general practitioners usually do not screen for PAD. ABI measurements need train-
ing, equipment and are time- consuming. No established simple and fast screening strategies
were available.
While PAD is sufficiently prevalent for screening, increases all-cause and cardiovascular
mortality by 2–3 fold and an accurate test (ABI measurement) is available, adequately powered
studies on morbidity and mortality reduction and cost-effectiveness of screening have been
lacking[8]. However, in the VIVA study, a combined screening approach for PAD
(ABI < 0.90 or> 1.4), abdominal aortic aneurysm and hypertension screening versus no
screening was tested in 50156 Danish men at age 65–74 years[9]. Screened men, in which one
of the above mentioned diseases were found, received pharmacologic treatment (in PAD, daily
doses of 75 mg aspirin and 40 mg simvastatin) along with instructions on diet, smoking cessa-
tion and exercise. In the screening group, a 7% lower mortality was achieved after a median
follow-up of 4.4 years at a cost of € 2148 per gained quality adjusted life year. This result
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therefore challenges the current guideline recommendation not to prescribe aspirin in patients
with asymptomatic PAD[1].
Ankle-brachial index
The most important criterion for the definition of peripheral arterial disease (PAD) is an
ankle-brachial index (ABI) below 0.90. Low ABI is associated with increased mortality and
morbidity[10]. Thereby, ABI is not only a diagnostic, but also an important prognostic marker
[11]. In clinical routine, ABI measurements are rarely performed, unless claudication symp-
toms have been mentioned by the patient. These measurements are usually only performed by
vascular specialists for diagnosis of PAD and follow-up after interventional or surgical PAD
treatment. Use of ABI measurements is also hampered by lack of adequate financial compensa-
tion in most areas of Germany.
Claudication
Claudication as a major clinical symptom of PAD could also be identified as an independent
predictor of increased mortality based on data from the population-based Study of Health in
Pomerania (SHIP)[12]. Of note, in this study claudication was defined on the basis of a posi-
tive answer to only one question asking for pain or cramps in the leg(s) during normal walking
for the main analysis. Traditionally, in population-based or large clinical studies, different
questionnaires were used to define claudication. Often, the Rose Questionnaire[13–17], Edin-
burgh Questionnaire[18] or Framingham Questionnaire[19–21] were used. Development of
the Rose questionnaire, which has widely been used since its first publication in 1962[22], was
based on a small number of patients. While being highly specific (90–100%) in comparison to
the diagnosis of intermittent claudication made by a physician, it is not very sensitive (60–
68%)[23]. The Edinburgh questionnaire, a simplified modification of the Rose questionnaire,
improves sensitivity (91%) and specificity (99%), which was likewise evaluated in comparison
to the clinical evaluation of a physician[23] (4). Using questionnaires enables the identification
of some symptomatic patients, but is time-consuming and currently not established in primary
medical care. However, one question asking for pain in the leg(s) during normal walking
could easily be integrated in the ascertainment of a routine medical history.
Association between claudication and ABI
Large studies analyzing the association between claudication and ABI are missing. Therefore, we
performed a meta-analysis within the German Epidemiological Peripheral Arterial Disease
(GEPArD) consortium using cross-sectional data from seven population-based cohort studies to
investigate the association between claudication and ABI in both sexes, using different definitions
of claudication, ranging from one single question to the Edinburgh Questionnaire. Data from
seven well-established cohort studies, which cover different regions of Germany, were analyzed.
This analysis was performed, because PAD awareness would be significantly improved if
many patients could be identified by a single question of a general practitioner. As individuals
with severe PAD are more likely to actively seek physician’s advice, it would especially be of
great help to identify those with mild PAD.
Methods
The GEPArD consortium and study population
This consortium was founded to jointly perform analyzes on PAD-related research questions
using epidemiological data from different German regions. For the current analyses we included
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data from all recent German population-based cohorts with data on claudication and ABI, we are
aware of. Cross-sectional data from seven population-based cohorts were available: Cardiovascular
disease, living and ageing in Halle (CARLA)[24], Gutenberg Health Study (GHS)[25, 26], Heinz-
Nixdorf-Recall-Studie (HNR)[27, 28], Cooperative Health Research in the Region of Augsburg
(KORA) F3, KORA F4[29, 30], and the Study of Health in Pomerania (SHIP)-2, SHIP-TREND
[31]. The studies comply with the Declaration of Helsinki, the locally appointed ethics committees
have approved the research protocols (CARLA: Ethics Committee of the Medical Faculty of the
Martin- Luther- University Halle- Wittenberg; GHS: Ethics committee of the State Medical Coun-
cil of Rhineland-Palatinate; HNR: Ethics Committee of the Essen University Hospital; KORA: Eth-
ics committee of the Bavarian Chamber of Physicians; SHIP: Ethics Committee of the University
of Greifswald) and informed consent has been obtained from all participants. For this meta-analy-
sis anonymized data from participants of 7 population-based cohorts were analyzed.
Inclusion and exclusion criteria
The above mentioned seven population-based cohorts included men and women who were
randomly selected from regional population registries, if they followed the invitation to take
part. For this analysis, all participants of these studies with valid data on claudication, ABI and
covariates were included. Participants with prior percutaneous transluminal angioplasty or
bypass surgery of peripheral arteries, who were already diagnosed with PAD, were excluded
from this analysis.
Assessment of claudication, ABI and covariates
Ankle and brachial blood pressure values were obtained from the first examination of each
participating study. In all studies, the highest ankle pressure of each leg was documented and
then the leg with the lower ankle pressure was used for the calculations of this analysis. An
ABI < 0.90 was defined as low ABI. Claudication was analyzed according to different ques-
tionnaires or a single question (Table 1). The association between claudication and ABI was
Table 1. Claudication questions.
Question # Definition 1 Definition 2 Definition 3 (Edinburgh questionnaire)
1 Do you get a pain in either
leg on walking?
(Yes, No)
Do you get a pain or discomfort in your leg(s)
when you walk?
(Yes, No, I am unable to walk)
Do you get a pain or discomfort in your leg(s) when you walk?
(Yes, No, I am unable to walk)
2 Does this pain ever begin when you are standing
still or sitting?
(Yes, No)
Does this pain ever begin when you are standing still or sitting?
(Yes, No)
3 Alternative 1 (from Rose questionnaire): Do you get this pain in your
calf (or calves)?
(Yes, No)
Alternative 2 (from pain localization drawing of the Edinburgh
questionnaire): „yes”if pain is localized in calf/calves
4 Do you get it if you walk uphill or hurry?
(Yes, No)
Do you get it if you walk uphill or hurry?
(Yes, No)
5 Do you get it when you walk at an ordinary pace
on the level?
(Yes, No)
Do you get it when you walk at an ordinary pace on the level?
(Yes, No)
6 What happens to it if you stand still?
(Usually continues more than 10 minutes, Usually
disappears in 10 minutes or less)
What happens to it if you stand still?




All studies CARLA, GHS, KORA F3, KORA F4 GHS, KORA F3, KORA F4
https://doi.org/10.1371/journal.pone.0224608.t001
Claudication and ABI
PLOS ONE | https://doi.org/10.1371/journal.pone.0224608 November 4, 2019 4 / 14
analyzed for three different claudication definitions. Definition 1 used just one question on
pain or cramps in the legs while walking. Definition 3 used the questions of the Edinburgh
questionnaire (in GHS participants were asked if they experience pain in the calf/calves instead
of drawing pain localization in the calf/calves), in definition 2 the question on pain localization
in the calf was left out.
Information on covariates was derived from interviews or by standardized measurements.
Smoking status was classified as never/ex-smokers or current smokers. Hypertension was
defined by either self-reported use of antihypertensive medication or a systolic BP�140
mmHg and/or a diastolic value� 90 mmHg (calculated by mean of the second and third value
out of three measurements, assessed after a 5 min resting period in sitting position). Diabetes
mellitus was defined by self-reported physician’s diagnosis or use of antidiabetic medication
(ATC code A10) or by HbA1c�6.5%. Use of lipid modifying medication was assessed based
on ATC coding (code C10). Waist circumference (WC) was assessed to the nearest 0.1 cm
using an inelastic tape measure. Serum levels of low density lipoprotein (LDL) and high den-
sity lipoprotein (HDL) cholesterol were assessed by the methods described for each cohort
previously.
Statistical analyses
The association between claudication with continuous ABI values was analyzed in a linear
regression analysis for each cohort separately. Likewise, the association between claudication
with low ABI values was analyzed in a logistic regression analysis on cohort-level. The results
of the population-based studies were then pooled in a meta-analysis. Study-specific effect sizes
for the association between claudication and ABI were combined to a pooled effect size by ran-
dom-effect meta-analysis[32]. Random effects were applied because the I2 pointed towards
heterogeneity of the estimates across the studies assuming that the true effect sizes are signifi-
cantly different between the studies as indicated by the p-value for heterogeneity provided in
the graphics. Meta-analysis was conducted using the metan command in STATA 13.1 (Stata
Corporation, College Station, TX, USA). Based on data from the largest cohort, GHS, addi-
tionally sensitivity and specificity of each of the three definitions to detect low ABI was calcu-
lated for two different age-groups (�55 to<65 years,�65 to<75 years). The methods were
carried out in accordance with the relevant guidelines and regulations.
Results
Overall data of 27,945 subjects (14,052 women, age range 20–84 years) could be included into
the respective analyses. Characteristics of the samples are shown in Table 2.
Frequencies of claudication and ABI values
The proportion of participants complaining of claudication varies largely between the different
cohorts with a minimum of 5.7% (HNR) and a maximum of 31% (CARLA) when definition 1
(asking one question for pain in the leg/ legs one walking) (Table 2) was used. According to
the definitions 2 and 3 (Table 2), the proportion of affected subjects is markedly lower with
much smaller inter-cohort differences (between 1.4% in GHS for definition 3 and 5.5% in
KORA F4 for definition 2).
The unadjusted mean ABI reached from 1.04 to 1.19 among the participating studies, while
the proportion of participants with low ABI varied between 1.2% and 6.2% (Table 1).
Claudication and ABI
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Association between claudication and ABI
For claudication definition 1, the meta-analysis demonstrated a significant negative associa-
tion between claudication and ABI, which was more pronounced in men. Specifically, men
with claudication had a 0.07 units lower ABI than those without claudication (95% confidence
interval -0.10, -0.04; p<0.001) (Fig 1). This difference was markedly smaller in women (ß =
-0.02; 95% confidence interval -0.02, -0.01; p<0.001) (Fig 2). Furthermore, in logistic regres-
sion analysis claudication was associated with a significantly higher probability for an ABI
<0.90 and this association was stronger in men (odds ratio 5.4; 95% confidence interval 4.20,
6.96; p<0.001) (Fig 3) compared to women (odds ratio 1.99; 95% confidence interval 1.58,
2.51; p<0.001) (Fig 4).
For claudication definitions 2 and 3, effect sizes and Odds Ratios increase with increasing
complexity of the definitions, both in men and women. For definition 3, which is only avail-
able in both KORA studies and GHS, though, Odds Ratio for low ABI is 13.99 (95% confidence
interval 9.37, 20.89; p<0.001) in men and 8.16 (95% confidence interval 2.98, 22.32; p<0.001)
in women.
Sensitivity and specificity of claudication definitions
Calculation of sensitivity and specificity of each of the three definitions to detect low ABI,
based on data from the largest cohort, GHS, revealed a low sensitivity for all definitions which
decreases markedly from definition 1 to 3. The specificity is very high (>90%) for all claudica-
tion definitions with a slightly lower value for definition 1 as compared to definitions 2 and 3
(Table 3).
Table 2. Characteristics of study samples.
Characteristic CARLA KORA F3 KORA F4 GHS HNR SHIP-2 SHIP-TREND
N 1779 2901� 1730� 14342 3252 1386 2555
Age, years 64 (55; 73) 57 (46; 67) 64 (58; 71) 55 (46; 64) 59 (53; 66) 57 (46; 67) 53 (41; 64)
Men, n (%) 967 (54 %) 1413 (48.7%) 857 (49.5%) 7165 (50.0%) 1535 (47.2%) 686 (49%) 1270 (50%)
Hypertension, n (%) 1405 (79 %) 1439 (49.6%) 902 (52.1%) 7094 (49.5%) 1863 (57.3%) 731 (53%) 1200 (47%)
Diabetes mellitus, n (%) 274 (15 %) 226 (7.8%) 178 (10.3%) 1305 (9.1%) 377 (11.6%) 184 (13%) 275 (11%)
Family History of MI, n (%)�� 105 (6%) 75 (2.6%) 79 (4.6%) 2355 (16.4%) n.a. 48 (3.5%) 73 (2.9%)
Family History of stroke, n (%)�� 69 (4%) 63 (2.2%) 49 (2.8%) 1278 (8.9%) n.a. 38 (2.8%) 45 (1.8%)
Smoking status Current smoker,
n (%) Ex-smoker, n (%) Never
smoker, n (%)




















Total cholesterol, mmol/L 5.44 (4.81;
6.13)
5.58 (4.94; 6.26) 5.72 (5.07; 6.41) 5.67 (4.97; 6.37) 5.93 (5.25; 6.57) 5.40 (4.70;
6.20)
5.40 (4.70; 6.20)
HDL cholesterol, mmol/L 1.33 (1.10;
1.63)
1.45 (1.19; 1.76) 1.40 (1.17; 1.68) 1.42 (1.19; 1.74) 1.50 (1.19; 1.78) 1.40 (1.16;
1.67)
1.40 (1.17; 1.66)
LDL cholesterol, mmol/L 3.22 (2.65;
3.83)
3.28 (2.71; 3.83) 3.59 (3.00; 4.22) 3.55 (2.95; 4.17) 3.77 (3.13; 4.37) 3.33 (2.70;
3.97)
3.35 (2.72; 3.98)
Lipid lowering drugs, n (%) 295 (17 %) 313 (10.8%) 327 (18.9%) 1881 (13.1%) 434 (13.4%) 260 (19%) 353 (14%)
Waist circumference, cm 100 (92; 108) 95 (85.4, 103.5) 96.55 (88.40;
105.1)
93.6 (84.7; 103.1) 103.0 (96.3;108.2) 92 (82; 101) 90 (80; 100)
Claudication Definition 1
Definition 2 Definition 3
552 (31 %) 36









185 (5.7%)—- 130 (9.4)—- 194 (7.6%)—-
Mean ABI 1.19 (1.12;
1.26)
1.12 (1.05; 1.20) 1.16 (1.08; 1.23) 1.04 (0.99; 1.10) 1.10 (1.03; 1.18) 1.12 (1.07;
1.18)
1.12 (1.07; 1.18)
Decreased ABI (<0.9) 77 (4.4 %) 108 (3.7%) 96 (5.5%) 763 (5.3%) 202 (6.2%) 33 (2.4%) 31 (1.2%)
https://doi.org/10.1371/journal.pone.0224608.t002
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Discussion
Improving PAD awareness
Focusing on cardiovascular and cerebrovascular event prevention, we need to identify early
PAD stages in order to be able to reduce morbidity and mortality rates in these individuals.
Our analysis demonstrates the advantages of a simple first step- screening strategy for PAD
which markedly improves sensitivity accompanied by minor declines in specificity in compari-
son to a more complex questionnaire. Adopting this single question about pain or cramps in
the legs during normal walking in history taking of general practitioners would help to achieve
Fig 1. Association between claudication (definition 1) and ABI in men.
https://doi.org/10.1371/journal.pone.0224608.g001
Fig 2. Association between claudication (definition 1) and ABI in women.
https://doi.org/10.1371/journal.pone.0224608.g002
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the guideline requirement to implement and support medical and public awareness of PAD
[1]. This would certainly identify only a minority of individuals with PAD, but that is still a lot
better than identifying none.
The narrow 95% confidence intervals overall and especially in the largest cohort (GHS) (Fig
1) demonstrate, that ABI differences were consistent between men with and without pain or
cramps in the legs during normal walking.
Patient workup
This single, simple question for claudication should serve as first screening step in all patients
of a general practitioner who are at least 40 years old, as PAD prevalence already reaches 5% in
Fig 3. Association between claudication (definition 1) and low ABI in men.
https://doi.org/10.1371/journal.pone.0224608.g003
Fig 4. Association between claudication (definition 1) and low ABI in women.
https://doi.org/10.1371/journal.pone.0224608.g004
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women and men at age 45–49 years in high- income countries[3]. If individuals answer “yes”
to this claudication question, the next step should be an ABI measurement. A primary ABI
screening in the above mentioned patients would be preferable, as individuals with asymptom-
atic PAD could also be identified. However, despite falling costs of automated devices for ABI
measurement, which enable less time-consuming and easier ABI screening, they are not yet
widely available among general practitioners (also due to reimbursement issues), making a pri-
mary ABI assessment currently not feasible.
In diabetics, additionally an oscillography, a duplex ultrasound of the lower extremity arter-
ies and/or toe-brachial index (TBI) measurements should be performed, as ABI measurements
may not be correct in individuals with mediasclerosis of the leg arteries. In this analysis, we
did not account for elevated resting ABI in diabetics. As we focus on detection of PAD at an
early stage, we decided not to exclude subjects with known diabetes mellitus, because primary
care physicians and patients may not know about diabetes mellitus at first presentation. It is
reassuring to see significant results even with the inclusion of diabetics.
If PAD is diagnosed, patients should be treated according to current guidelines. This should
include statin therapy[5] and a platelet aggregation inhibitor like aspirin or clopidogrel. Con-
sidering the results of the COMPASS PAD trial, patients with stable symptomatic PAD will
probably soon receive a combination of aspirin and low-dose rivaroxaban[33].
If patients answer “no” to this claudication question, this does not exclude the presence of
asymptomatic PAD. Further work-up for PAD should especially be considered in patients
with diabetes, hypertension, hypercholesterolemia, positive family history of atherosclerotic
disease, impaired renal function and smokers. It has been demonstrated, that even mild-to-
moderate chronic kidney disease is associated with an increased risk of incident PAD[34].
Patients with known coronary artery disease usually do not need further work-up for asymp-
tomatic PAD, as preventive measures will usually not change and interventional or surgical
therapy of asymptomatic PAD is not indicated[1].
Claudication definitions
Claudication- definition 1 is unspecific and may include “claudication” from non-ischemic causes.
Claudication- definition 3 (Edinburgh Questionnaire) markedly underestimates PAD according to
ABI<0.90—definition. While the Edinburgh Questionnaire was found to be highly sensitive in
comparison to a subjective physician diagnosis of intermittent claudication, in this study it is not
very sensitive in comparison to the generally accepted PAD-diagnosis based on ABI-measurement.
There seems to be a relevant number of individuals, whose complaints do not meet the Edinburgh
questionnaire criteria, but who are PAD-patients according to ABI-measurement.
It is important to keep in mind that most PAD patients are asymptomatic. But if we manage
to motivate general physicians to ask their patients one question about claudication and
thereby identify 20–30% of patients with mild PAD (Table 3), this will be a huge step forward
in comparison to the present situation, in which the percentage of patients with mild PAD
(still being a silent “killer”) who are recognized in general practices is probably close to 0%.
Table 3. Sensitivity and specifity of claudication definitions to detect low ABI in GHS.
Age group 35 to 74 years 55 to < 65 years � 65 to 74 years
Definition Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Definition 1 23.6% [20.6; 26.8] 93.3% [92.9; 93.7] 28.5% [22.6; 35.1] 91.8% [90.8; 92.6] 32.6% [27.3; 38.2] 90.5% [89.5; 91.5]
Definition 2 11.8% [9.6; 14.3] 98.6% [98.4; 98.8] 15.0% [10.5; 20.4] 98.3% [97.9; 98.7] 16.1% [12.1; 20.8] 98.0% [97.5; 98.5]
Definition 3 9.8% [7.8; 12.2] 99.1% [98.9; 99.2] 12.6% [8.5; 17.8] 99.0% [98.6; 99.3] 13.4% [9.8; 17.8] 98.7% [98.2; 99.0]
https://doi.org/10.1371/journal.pone.0224608.t003
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PAD-patients suffer from a bad prognosis. Therefore, early identification of these patients,
which enables modification of risk factors and early pharmacological treatment, seems impor-
tant. Consequentially, the higher sensitivity of an unspecific question seems more important
than the slightly higher specificity of a complex questionnaire. In our opinion, it is about time
to leave the traditional questionnaires in favor of one simple question. The data of our meta-
analysis support to include this very simple one-item questionnaire into the daily clinical prac-
tice and into angiological and other vascular guidelines. Future claudication questionnaires
should be evaluated in comparison with ABI measurements, not in comparison with the clini-
cal evaluation by a physician. The analysis of the GHS data is in accordance with the results of
the meta-analysis supporting the application of one question on claudication when screening
for PAD.
PAD symptoms in women
One question about claudication (definition 1) can identify individuals with a high likelihood
of low ABI. The weaker association in women when compared to men could point to a differ-
ent–so far unrecognized- clinical presentation of PAD in women. Already in 1982, a study
from Finland demonstrated that the validity of “typical” claudication symptoms was poorer in
women than in men and they were also less reliable predictors of death in women[15]. The
Rose Questionnaire was evaluated in 55 patients, among them 37 with “undoubted intermit-
tent claudication” (rather meaning undoubted PAD)[22]. Among these 37, only 5 were
women, which makes it very likely that typical PAD symptoms in women besides claudication
were not recognized. In coronary artery disease, the different clinical presentation in women
in comparison to men remained unrecognized for decades. We need future studies looking for
so far unrecognized PAD symptoms in women.
PAD screening by ABI measurement
To our knowledge this is the largest analysis of the association between claudication and ABI
in population-based studies. Our data demonstrate that even one simple question about clau-
dication can help to identify individuals with PAD. However, these results do not negate the
advantages of a PAD screening by ABI measurement. An ABI measurement allows to identify
the large group of individuals with asymptomatic PAD[35], especially among older women.
ABI measurements may be less time-consuming and cheaper than PAD prediction models
which depend among others on laboratory values[36]. With the availability of simple and
user-friendly-automated systems for the evaluation of ABI, PAD screening by ABI measure-
ments has become easier. But as long as ABI screenings are not established in health care sys-
tems, asking one quick, simple question for claudication is clearly preferable to no PAD
screening.
Limitations
Some limitations have to be taken into account. The Edinburgh questionnaire for evaluation
of claudication was not used in all studies of the present analysis. The number of participants
varied widely among the studies. Rates of claudication and low ABI increase markedly at
higher age, age groups were not homogenous in the seven population-based studies. The avail-
able data were not sufficient for calculation of the association between claudication and an
alternative ABI calculation using the lowest leg pressure[37]. The perception of claudication
may be influenced by exercise training [38], but this should be of lower importance in popula-
tion-based studies.
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Conclusion
At least in men, one claudication question [asking for pain or cramps in the leg(s) during nor-
mal walking] can identify many individuals with a high likelihood of PAD and should be
established as first screening step.
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Claudication and ABI
PLOS ONE | https://doi.org/10.1371/journal.pone.0224608 November 4, 2019 11 / 14
Formal analysis: Claudia Lamina, Susanne Moebus, Daniel Tiller, Roberto Lorbeer, Andreas
Schulz, Christa Meisinger, Daniel Medenwald, Raimund Erbel, Alexander Kluttig, Till
Ittermann.
Investigation: Arne Georg Kieback, Christine Espinola-Klein, Claudia Lamina, Susanne Moe-
bus, Daniel Tiller, Marcus Dörr.
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